Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPIZA: IP Sintilimab and Zoledronic Acid for Gastric Cancer Ascites
NCT06759064Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), malignant ascites, sponsored by Qilu Hospital of Shandong University. Started Sep 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)malignant ascites
Beyond the preview
Go deeper on NCT06759064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759064.